CLINICAL TRIALS
Based on research conducted in our laboratory, we have launched or contributed to several immunotherapy clinical trials. For more information about these trials, click the links below.
Phase III Trial in Prostate Cancer (Trial is open and enrolling)
​
This is a phase III clinical trial comparing high-dose rate versus low-dose rate brachytherapy (radioactive seeds) as a single treatment for intermediate risk prostate cancer. This study is currently active and recruiting patients. We are collaborating with the study investigator Dr. Juanita Crook to understand, a) whether we can predict which patients will respond to brachytherapy, and b) whether the immune system plays a role in patient responses.
For more information, click here.
Photo credit: BC Cancer Foundation
CLINICAL STUDIES
Intermittent Fasting Feasibility Study in CLL (Study is open and enrolling)
​
The investigators plan to examine the effects of intermittent fasting (time restricted feeding) in patients with chronic lymphocytic leukemia (CLL). CLL is the most common chronic leukemia and is presently incurable. The advantage of choosing this patient population is that the cancer is easily assessed with a blood test measuring the amount of cancerous white cells (lymphocytes). Patients who consent to participate in this study will, through the support of an oncology dietitian and after a period of transition, split their daily feeding into a fasting period and a non-fasting period. This regime is as simple as skipping or having a late breakfast. At this time, participants will not be required to limit their total caloric intake.
​
For more information about participating in the study please contact the Study Coordinator.​
​
Immune Response to Ovarian Cancer (IROC) (Study is open and enrolling)
We are actively studying how the immune systems responds to ovarian cancer. Through our human biospecimen repository, our team is investigating the metabolic interactions between tumors and T cells using mass-spectometry and high-dimensional analysis. This work involves the collection of biospecimens from ovarian cancer patients treated at our cancer centre. The studies will also include the discovery of novel neoantigens that could be targets for CAR-T cell or adoptive T cell immunotherapy strategies. The goal is to generate important knowledge about the behavior of ovarian cancers and how best to harness the immune system to attack the cancer cells. The study is a large team effort by multiple laboratories across multiple disciplines.
For more information about the study, please contact a member of the Study team.
​